Free Trial
NASDAQ:MRSN

Mersana Therapeutics (MRSN) Stock Price, News & Analysis

Mersana Therapeutics logo
$7.75 -0.36 (-4.44%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$7.76 +0.01 (+0.19%)
As of 08/22/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mersana Therapeutics Stock (NASDAQ:MRSN)

Key Stats

Today's Range
$7.71
$8.19
50-Day Range
$5.97
$10.14
52-Week Range
$5.21
$70.75
Volume
71,731 shs
Average Volume
130,808 shs
Market Capitalization
$38.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.60
Consensus Rating
Buy

Company Overview

Mersana Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

MRSN MarketRank™: 

Mersana Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 176th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mersana Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Mersana Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mersana Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mersana Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    8.01% of the float of Mersana Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 94.96%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mersana Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mersana Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.01% of the float of Mersana Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 94.96%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Mersana Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 4 people have searched for MRSN on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mersana Therapeutics' insider trading history.
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

Q3 Earnings Estimate for MRSN Issued By Leerink Partnrs
Q3 EPS Forecast for Mersana Therapeutics Lifted by Analyst
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.tc pixel
Research Analysts Offer Predictions for MRSN Q3 Earnings
See More Headlines

MRSN Stock Analysis - Frequently Asked Questions

Mersana Therapeutics' stock was trading at $35.75 at the beginning of 2025. Since then, MRSN shares have decreased by 78.3% and is now trading at $7.75.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its quarterly earnings results on Wednesday, August, 13th. The company reported ($4.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.75) by $0.33. The firm earned $3.06 million during the quarter, compared to analyst estimates of $6.06 million. Mersana Therapeutics had a negative net margin of 212.94% and a negative trailing twelve-month return on equity of 990.16%.
Read the conference call transcript
.

Mersana Therapeutics shares reverse split on the morning of Friday, July 25th 2025.The 1-25 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Mersana Therapeutics (MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Top institutional investors of Mersana Therapeutics include 683 Capital Management LLC (39.88%), Geode Capital Management LLC (21.03%), Jane Street Group LLC (10.24%) and Cerity Partners LLC (6.43%). Insiders that own company stock include Timothy B Lowinger, Anna Protopapas, Martin H Jr Huber, Brian Deschuytner, Alejandra Carvajal, Ashish Mandelia, Mohan Bala, Arvin Yang and Tushar Misra.
View institutional ownership trends
.

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/13/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRSN
CIK
1442836
Fax
N/A
Employees
150
Year Founded
2005

Price Target and Rating

High Price Target
$125.00
Low Price Target
$17.00
Potential Upside/Downside
+630.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.19 million
Net Margins
-212.94%
Pretax Margin
-211.74%
Return on Equity
-990.16%
Return on Assets
-54.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.35
Quick Ratio
1.35

Sales & Book Value

Annual Sales
$40.50 million
Price / Sales
0.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($10.65) per share
Price / Book
-0.73

Miscellaneous

Outstanding Shares
4,990,000
Free Float
4,342,000
Market Cap
$38.67 million
Optionable
Optionable
Beta
0.83

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:MRSN) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners